By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Protagonist Therapeutics 

Menlo Business Park
1455 Adams Drive, Suite 2003
Menlo Park  California   94025  U.S.A.
Phone: 650-587-5766 Fax:


Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.




Founder: Mark Symythe

CEO: Dinesh Patel

CMO (Marketing): Richard Shames

CFO: Tom O’Neil

CSO (Scientific): David Liu


Please click here for Protagonist Therapeutics job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Protagonist
Symbol: PTGX


Company News
Bay Area's Protagonist (PTGX) Raises $90 Million in Upsized IPO 8/11/2016 7:30:46 AM
Protagonist Therapeutics, a GI Biotech, Sets Terms for $70 Million IPO 8/1/2016 9:17:43 AM
Protagonist Therapeutics Receives SBIR Funding For The Development Of Injectable Hepcidin Mimetics For Treatment Of Iron Overload Disorders 7/28/2016 6:50:42 AM
William D. Waddill, Calithera Biosciences, Inc. (CALA) CFO, Elected To Protagonist Therapeutics Board 7/8/2016 7:31:05 AM
Protagonist Therapeutics To Present New Data For PTG-100 And PTG-200 At Digestive Disease Week 2016 5/17/2016 8:12:45 AM
Protagonist Therapeutics Names Thomas P. O'Neil Chief Financial Officer 2/17/2016 6:19:27 AM
Protagonist Therapeutics Initiates Phase 1 Study With Oral Peptide PTG-100 1/8/2016 6:31:53 AM
Protagonist Therapeutics Receives SBIR Funding For Oral IL-23 Receptor Antagonists For Treatment Of Inflammatory Bowel Diseases 9/24/2015 11:09:45 AM
Protagonist Therapeutics Names Richard S. Shames, M.D. As Chief Medical Officer 9/10/2015 7:15:24 AM
Bay Area's Protagonist Therapeutics Fetches $40 Million to Bring Next-Gen IBD Drugs to Trial 7/16/2015 6:05:43 AM